US6007992A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pyrimidine derivatives for labeled binding partners
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1997-11-10
•
Granted: 1999-12-28
•
Expires: 2017-11-10
Abstract
Abstract Compounds having structure (1) ##STR1## wherein R 1 is --H a protecting group, a linker or a binding partner; and R 2 and R 34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
Inventors
- 👤 Kuei-Ying Lin
- 👤 Mark D. Matteucci
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:56
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H21/00; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6813; C12Q2525/00; C12Q2525/10; C12Q2525/101; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
177 words
A method comprising mixing a compound having the structure (1): ##STR37## and tautomers, solvates and salts thereof, wherein R 1 is an oligonucleotide, a protecting group, a linker, or H; R 2 is A(Z) X1 , wherein A is a spacer and Z independently is a label bonding group optionally bonded to a detectable label, but R 2 is not amine, protected amine, nitro or cyano; R 27 is independently --CH═, --N═, --C(C 1 -C 8 alkyl)═ or --C(halogen)═, but no adjacent R 27 are both --N═, or two adjacent R 27 are taken together to form a ring having the structure, ##STR38## where Ra is independently --CH═, --N═, --C(C 1 -C 8 alkyl)═ or --C(halogen)═, but no adjacent Ra are both --N═, R 34 is --O--, --S--, or --N(CH 3 )--; and X1 is 1, 2 or 3; with a sample suspected of containing a target nucleic acid having a base sequence that is substantially complementary or complementary to the compound's base sequence to form a mixture and optionally incubating the mixture to form a complex.
Claim 2
Independent Claim
177 words
A method comprising mixing a compound having the structure (1): ##STR37## and tautomers, solvates and salts thereof, wherein R 1 is an oligonucleotide, a protecting group, a linker, or H; R 2 is A(Z) X1 , wherein A is a spacer and Z independently is a label bonding group optionally bonded to a detectable label, but R 2 is not amine, protected amine, nitro or cyano; R 27 is independently --CH═, --N═, --C(C 1 -C 8 alkyl)═ or --C(halogen)═, but no adjacent R 27 are both --N═, or two adjacent R 27 are taken together to form a ring having the structure, ##STR38## where Ra is independently --CH═, --N═, --C(C 1 -C 8 alkyl)═ or --C(halogen)═, but no adjacent Ra are both --N═, R 34 is --O--, --S--, or --N(CH 3 )--; and X1 is 1, 2 or 3; with a sample suspected of containing a target nucleic acid having a base sequence that is substantially complementary or complementary to the compound's base sequence to form a mixture and optionally incubating the mixture to form a complex.
Claim 3
Dependent Claim
51 words
The method of claim 1 wherein the compound and the target nucleic acid form a complex having a Tm of about 85 to 95° C., optionally heating the complex to about 85 to 95 ° C. to provide a heated complex, and optionally mixing the heated complex with a DNA polymerase.
Claim 4
Dependent Claim
201 words
The method of claim 1 wherein R 1 has the structure: ##STR39## wherein D is --OH, protected --OH, an oligonucleotide coupling group or a solid support; D 1 is an oligonucleotide coupling group, --OH, protected --OH, or a solid support, wherein D 1 is bonded to one 2' or 3' position in the oligonucleotide of structure (2) and the adjacent 2' or 3' position in structure (2) is substituted with R 21 , provided that D and D 1 are not both an oligonucleotide coupling group or they are not both a solid support; R 4 is independently a phosphodiester linkage or a phosphodiester substitute linkage, wherein R 4 is bonded to one 2' or 3' position in the structure (2) oligonucleotide and the adjacent 2' or 3' position in structure (2) is substituted with R 21 ; R 21 is independently --H, --OH, halogen or a moiety that enhances the oligonucleotide against nuclease cleavage; R 37 is independently --O--, --CH 2 -- or --CF 2 --; n is at least about 7; and B independently is a purine or pyrimidine base or a protected derivative thereof, provided that at least one B is a base of structure (3), ##STR40## .
References Cited (Backward Citations)
US4233402A
Cited
JPS6259293A
Cited
US5286717A
Cited
WO1988010264A1
Cited
WO1990015065A1
Cited
WO1991006626A2
Cited
WO1991006629A1
Cited
WO1992002258A1
Cited
US5614617A
Cited
EP0487289A2
Cited
WO1992020702A1
Cited
EP0541153A1
Cited
US5594121A
Cited
WO1993010820A1
Cited
US5645985A
Cited
WO1993013121A1
Cited
WO1993024507A1
Cited
US5502177A
Cited
US5623068A
Cited
WO1996005298A1
Cited
WO1996037504A1
Cited
US5614622A
Cited
US5668272A
Cited
US5728528A
Cited
WO1997014706A1
Cited
WO1997028176A1
Cited
WO1997031008A1
Cited
WO1997032888A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-12-27 | 2003-06-28 | 2003-12-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-12-27 | 2007-06-28 | 2007-12-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-12-27 | 2011-06-28 | 2011-12-28 | $7700.00 | Window Closed / Lapsed |